Quanterix announces collaborations with health systems

Quanterix announced its first collaborations with health systems in pursuit of their shared goal to improve and simplify Alzheimer’s disease, or AD, diagnosis. These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays. Collectively AdventHealth, Mass General Brigham, Mayo Clinic, South Carolina Alzheimer’s Disease Research Center at the Medical University of South Carolina, and UPMC represent 140+ hospitals across 18 states, caring for approximately 21M patients in their hospital networks. This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.